NCT05843253 2026-04-22
Study of Ribociclib and Everolimus in HGG and DIPG or Ribociclib and Temozolomide in DHG, H3G34-mutant
Nationwide Children's Hospital
Phase 2 Recruiting
Clinical Trials
13 trialsNCT07405801 2026-04-20
A Phase II Study Evaluating the Efficacy and Safety of Inavolisib Plus Ribociclib Plus Fulvestrant Versus Placebo Plus Ribociclib Plus Fulvestrant in Participants With Advanced Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT05467891 2026-04-08
RaPhLRR
Hoosier Cancer Research Network
Phase 2 Recruiting
NCT07054190 2026-03-31
A Study to Test Inavolisib Treatments in Participants With Early-Stage, PIK3CA-Mutated Breast Cancer
Hoffmann-La Roche
Phase 2 Recruiting
NCT06409390 2025-12-04
Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Recruiting
NCT04116541 2025-11-21
MegaMOST
Centre Leon Berard
Phase 2 Recruiting
NCT06062498 2025-10-20
Elacestrant vs Elacestrant Plus a CDK4/6 Inhibitor in Patients With ERpositive/HER2-negative Advanced or Metastatic Breast Cancer
Northwestern University
Phase 2 Recruiting
NCT05900206 2025-09-02
ARIADNE
Karolinska University Hospital
Phase 2 Recruiting
NCT06953882 2025-07-14
SELECT
Yale University
Phase 2 Recruiting
NCT05296746 2025-03-18
RIBOLARIS
SOLTI Breast Cancer Research Group
Phase 2 Recruiting
NCT05816655 2025-03-18
Comparison of Clinical Efficacy Between Letrozole + Ribociclib and Fulvestrant + Letrozole + Ribociclib in Hormone Receptor Positive, HER2 Negative Metastatic Breast Cancer
Korea University Guro Hospital
Phase 2 Recruiting
NCT02925234 2024-01-24
DRUP
The Netherlands Cancer Institute
Phase 2 Recruiting
NCT05766410 2023-03-16
ORACLE-RIPA
National Taiwan University Hospital
Phase 2 Recruiting